Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409280 | 1.00 | BACE1 (0.35) | BACE1KCNH2BACE2XDHSLC22A12 | |
| SCHEMBL315872 | 0.89 | CHRNB2 (0.36) | MKNK1MKNK2FGFR1 | |
| SCHEMBL315871 | 0.89 | CHRNB2 (0.36) | MKNK1MKNK2FGFR1 | |
| SCHEMBL2417047 | 0.86 | S1PR1 (0.39) | BACE1BACE2XDHSLC22A12FPR2 | |
| SCHEMBL2411961 | 0.86 | CYP11B1 (0.41) | BACE1BACE2MKNK1MKNK2 | |
| SCHEMBL2411825 | 0.86 | PRMT5 (0.39) | BACE1BACE2FPR2 | |
| SCHEMBL2411967 | 0.86 | CYP11B1 (0.41) | BACE1BACE2MKNK1MKNK2 | |
| SCHEMBL2417043 | 0.86 | S1PR1 (0.39) | BACE1BACE2XDHSLC22A12FPR2 | |
| SCHEMBL2411823 | 0.86 | PRMT5 (0.39) | BACE1BACE2FPR2 | |
| SCHEMBL2410200 | 0.86 | PRMT5 (0.35) | BACE1KCNH2FPR2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | BACE1 3683/4885KCNH2 3664/4885BACE2 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.